We are live on ! Find out more
IHE icon

iShares US Pharmaceuticals ETF

101 hedge funds and large institutions have $139M invested in iShares US Pharmaceuticals ETF in 2018 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 17 increasing their positions, 41 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

73% more call options, than puts

Call options by funds: $1.05M | Put options by funds: $605K

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

6% less funds holding

Funds holding: 108 → 101 (-7)

13.11% less ownership

Funds ownership: 48.71% → 35.59% (-13%)

44% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 16

59% less repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 41

94% less capital inflows, than outflows

Capital inflows: $8.98M | Capital outflows: $149M

Holders
101
Holders Change
-7
Holders Change %
-6.48%
% of All Funds
2.31%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
9
Increased
17
Reduced
41
Closed
16
Calls
$1.05​M
Puts
$605​K
Net Calls
+$443​K
Net Calls Change
+$150​K

IHE Hedge Fund Activity: Q1 2018 in Review

101 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in iShares US Pharmaceuticals ETF (IHE) for Q1 2018, worth a combined $139M — down 51% from $286M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of IHE and 9 opened new positions — a net loss of 7 holders — while 41 trimmed existing stakes and 17 added.

The largest buyer was Morgan Stanley, adding an estimated $2.98M. The largest seller was Clal Insurance, exiting entirely with an estimated $116M sold.

  • 101 institutional investors held iShares US Pharmaceuticals ETF (IHE) as of Q1 2018, down from 108 in Q4 2017.
  • Funds reported $139M of iShares US Pharmaceuticals ETF stock for Q1 2018, down 51% quarter-over-quarter.
  • 9 funds opened new iShares US Pharmaceuticals ETF positions in Q1 2018 and 16 closed out, a net change of -7 holders.
  • The largest iShares US Pharmaceuticals ETF buyer in Q1 2018 was Morgan Stanley, an estimated $2.98M added.
  • The largest iShares US Pharmaceuticals ETF seller in Q1 2018 was Clal Insurance, an estimated $116M sold.

Based on aggregated 13F filings for Q1 2018.